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The present investigation describes the inﬂuence of the concentration of PEG 6000 as a melt binder and ratio of HPMC K4M:PVP
on Zolpidem tartrate controlled-release tablet formulations using 32 full factorial design. The ratio of HPMC K4M and PVP K30
(X1) and the concentration of melt binder (X2) were selected as independent variables, and drug release at 1hr (Q1), 4hr (Q4), 8hr
(Q8), diﬀusion coeﬃcient (n), and release rate constant (K) were selected as a dependent variable. Tablets were prepared by melt
granulation technique and evaluated for various evaluation parameters. It was observed that concentration of melt binder had
signiﬁcant eﬀect on Q1, Q4, n,a n dK Binder concentration 25%w/w was found optimum. Optimized formulation (F7) showed
good similarity with theoretical proﬁle of drug. The X2 variable had a signiﬁcant eﬀect on dependent variables, and the X1 variable
had no signiﬁcant eﬀect on dependent variables.
1.Introduction
Controlled-release (CR) formulations have been introduced
into drug therapy with two main purposes: to reduce the
number of single doses per day improving patient compli-
ance of treatments and to decrease the ﬂuctuations of plasma
levels, in order to obtain better therapeutic eﬃcacy and low-
ertoxicity.Therearemanycontrolled-releasepharmaceutical
systems currently known, ranging from monolithic matri-
ces, membrane reservoirs, erodible polymers, to the more
technologically complex and sophisticated pH independent
formulations, ion exchange resins, osmotically, and geomet-
rically modiﬁed systems. Many of these systems are not
produced in a form that is amenable to large-scale manu-
facturing processes and usually do not exhibit the desirable
zero-order release kinetics. In addition, the cost of for-
mulation development, raw materials, and manufacture
technology are among the principal factors in CR delivery
systems formulation for oral dosing [1]. An interesting
approach to develop CR matrix formulations is based on
melt granulation, which is a very short and easy one-step
technique converting ﬁne powders into granules. The pow-
deragglomerationispromotedbytheadditionofalowmelt-
ing point binder, which is solid at room temperature and
melts at relatively low temperatures (50–80◦C). The interest
in melt granulation has increased due to the advantages of
this technique over other CR delivery technologies. Since it
is a solvent-free process, the drying phase is eliminated, and
thus it becomes less consuming in terms of time and energy
[2, 3].
Zolpidem is a nonbenzodiazepine analogue of imidazo-
pyridine class. Zolpidem tartrate is a GABA agonist (sedative
and hypnotic) used in the treatment of insomnia dosing
ranging from 5 to 12.5mg. The half life of the drug is
about 1.9 to 3hr, and oral bioavailability is 72 ± 7% indi-
cating its promising candidature for the controlled-release
formulation [4]. Zolpidem was marketed as the immediate
release product in the short-term treatment of insomnia.
Zolpidem is eﬀective in reducing the time to sleep onset
and increasing total sleep time; however, its eﬀect on sleep
maintenance has not been consistently demonstrated. The
hypnotic eﬀects of Zolpidem have been reported primarily
intheﬁrst3hourspostdosewhichcanleadtosubtherapeutic
eﬀects on sleep maintenance in the later portion of the night
for some patients [5]. So, it is desired to maintain plasma
concentration of drug for 8hr.2 ISRN Pharmaceutics
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Figure 1: In vitro dissolution proﬁle of factorial design batches.
Moreover, melt granulation is one of the most widely
applied processing techniques in the array of pharmaceutical
manufacturing operations due to its simplicity and easy
scaleup [6–8]. In recent years, melt granulation has also
been successfully employed to improve the dissolution rate
of poorly soluble compounds increasing the bioavailability
of these kinds of drugs, [9–11] and in the development of
CR formulations [12–14] and masking the bitter taste of an
active drug [15, 16].
Hence, the purpose of present investigation was to deve-
lope controlled-release tablet of Zolpidem tartrate by using
polyethylene glycol (PEG 6000) [17] as melt binder, Hydrox-
ypropylmethylcellulose(HPMCK4M)andPolyvinylpyrroli-
done (PVP K30) as matrixing agent and ﬁller, respectively,
which would release the drug for prolonged period of time
in view to maximize therapeutic eﬀect of the drug and in
an eﬀort to expand the coverage of sleep complaints and
overcome the lack of eﬃcacy in sleep maintenance.
2.MaterialsandMethods
2.1.Materials. ZolpidemtartratewasprocuredfromTripada
Pharmaceuticals Ltd., Ahmedabad, India. Hydroxypropyl
methylcellulose K4M (HPMC K4M) was obtained from
Yarrow Chem. Products, Mumbai, India. PEG 6000 and PVP
K30wereobtainedfromS.D.Finechemicals,Mumbai,India.
Lactose, Magnesium stearate, and talc were purchased from
Shakti Chemicals, Mehsana, India. All other materials and
chemicals used were of either pharmaceutical or analytical
grade.
2.2. Methods
2.2.1. Preparation of Zolpidem Controlled-Release Tablets by
Melt Granulation. Accurately weigh PEG 6000 was melted
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Figure 2: Response surface plot for Q1.
in a porcelain dish at 55–60◦C on heating metal, and the
accurate quantity of Zolpidem was added to the melted
mass of PEG. Previously prepared geometric mixture by
tumbling method using spatula for 14 minutes of HPMC
K4M, PVP, and Lactose was added to the molten Zolpidem-
PEG 6000 mixture and stirred well to mix. Then mass was
removed from the hot plate and subjected to scrapping until
it attained room temperature. The coherent mass was passed
through 22 mesh, and the resulting granules were resifted
over 44 meshes to separate granules and ﬁnes. The % loss
of mass during melt granulation was found between 15 and
20% of total weight. The granules were collected and mixed
with talc and magnesium stearate. The lubricated blend was
compressed using 8mm round ﬂat punch on 10 station
Rimek-Irotarytabletmachine(KarnavatiEngineering,Kadi,
India). Compression was adjusted to obtain tablets with
hardness in the range of 3-4kg/cm2.
2.2.2. Physical Characterization. The fabricated tablets were
characterized for weight variation (n = 20), hardness (n =
6) Pﬁzer hardness tester (Janki Instrument Ltd, Ahmedabad,
India), thickness using a screw-gauge micrometer (Campbell
Electronics, Mumbai, India), and % friability (n = 20, Roche
friabilator, Electrolab, Mumbai, India).
2.2.3. In Vitro Dissolution Study. The in vitro dissolution
studyofZolpidemtablets(n =3)wasperformedasdescribed
in Indian Pharmacopoeia 2010 using USP apparatus II
(model TDT-08T, Electrolab, Mumbai, India) ﬁtted with
paddle (50rpm) at 37◦C ± 0.5◦C using simulated gastric
ﬂuid (pH 1.2; 900mL) as a dissolution medium for ﬁrst 2ISRN Pharmaceutics 3
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Figure 3: Response surface plot for Q4.
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Figure 4: Response surface plot for Q8.
hours and followed by phosphate buﬀer (pH 6.8; 900mL)
for remaining hours. At the predetermined time intervals,
10-mL samples were withdrawn and analyzed at 238nm
using a Shimadzu UV 1800 double-beam spectrophotometer
(Shimadzu, Kyoto, Japan). Cumulative percentage drug re-
lease was calculated using an equation obtained from a cal-
ibrationcurvewhichisdevelopedintherangeof2–16μg/mL
for 0.1N HCl and pH-6.8 phosphate buﬀer (see Figure 1).
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Figure 5: Response surface plot for diﬀusion coeﬃcient (n).
−1
−0.5
0
1
0.5
0.4
0.5
0.6
0.7
0.8
0.9
1
0.5
0
−0.5
−1
k
A: polymer ratio
B:c on. of melt binder
Figure 6: Response surface plot for release rate constant (K).
2.2.4. Optimization of Variables Using Full Factorial Design.
A3 2 randomized full factorial design was employed in the
present study. In this design, 2 factors were evaluated, each
at 3 levels, and experimental trials were performed for all
9 possible combinations. The ratio of polymer (HPMC
K4M:PVP) (X1) and concentration of melt binder (PEG
6000) (X2) were chosen as independent variables in 32 full
factorial design, while Q1, Q4,a n dQ8 (% drug release after4 ISRN Pharmaceutics
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Figure 7: FTIR spectrum of Zolpidem tartrate.
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Figure 8: FTIR spectrum of granules of optimized batch.
1, 4, and 8 hours, resp.), diﬀusion coeﬃcient (n), and release
rate constant (K) were taken as dependent variables. The
composition of factorial design batches (F1–F9) is shown in
Table 1. The prepared formulations were evaluated for assay,
friability, and hardness and in vitro release study. The results
of evaluation parameters are shown in Table 2. Statistical
treatment was carried out to the factorial design batches
using design expert DX8 software.
2.2.5. Kinetic Modeling of Dissolution Data. The dissolution
proﬁle of all batches was ﬁtted to various models such as zero
order, ﬁrst order, Higuchi [18], Hixon and Crowell [19], and
Korsmeyer et al. [20], to ascertain the kinetic of drug release.
2.2.6. Comparison of Dissolution Proﬁles for Selection of
Optimum Batch. The similarity factor (f2)g i v e nb yS U P A C
guidelines for a modiﬁed release dosage form was used as a
basistocomparedissolutionproﬁles.Thedissolutionproﬁles
are considered to be similar when f2 is between 50 and 100.
The dissolution proﬁle of products was compared using an
f2 which is calculated from following formula:
f2 = 50 × log
⎧
⎪ ⎨
⎪ ⎩
⎡
⎣1+
 
1
n
  n  
t=1
wt(Rt −Tt)
2
⎤
⎦
−0.5
×100
⎫
⎪ ⎬
⎪ ⎭
,( 1 )
where n is the dissolution time, and Rt and Tt are the
reference (here, this is the theoretical dissolution proﬁle of
Zolpidem) and test dissolution value at time t [21].
2.2.7. Fourier Transform Infrared Spectroscopy. Fourier trans-
form infrared (FTIR) spectra of Zolpidem tartrate (see
Figure 7) and granules of optimized batch were recordedISRN Pharmaceutics 5
Table 1: Formulation and evaluation of batches in 32 full factorial design.
Batch code Variable levels in coded form Q1 Q4 Q8 nK
X1 X2
F1 −1 −1 81.33 99.67 100 0.084 0.868
F2 −1 0 63.91 91.76 98.29 0.188 0.686
F3 −1 1 78.73 99.6 100 0.097 0.848
F4 0 −1 74.91 99.19 100 0.128 0.802
F5 0 0 73.4 96.61 100 0.134 0.784
F6 0 1 55.58 88.14 100 0.268 0.603
F7 1 −1 43.22 75.26 96.82 0.379 0.44
F8 1 0 53.35 90.83 100 0.288 0.574
F9 1 1 43.9 73.32 93.33 0.356 0.446
Coded values Actual values
X1 X2
−1 25%:20% 15%
0 30%:15% 20%
1 35%:10% 25%
∗All batches contained 12.5milligrams of Zolpidem, 2.5mg of talc, and 1.25mg of magnesium stearate. X1 indicates the ratio of HPMC K4M (%): PVP (%),
and X2 is the concentration of melt binder PEG 6000. Q1, Q4,a n dQ8 indicate the percentage of drug released after 1, 4, and 8 hours, respectively. n and K
indicate diﬀusion coeﬃcient and release rate constant, respectively.
Table 2: Results of factorial design batches (F1–F9).
Parameter F1 F2 F3 F4 F5 F6 F7 F8 F9
Assay (%) 93.45 97.43 92.50 91.45 94.62 96.08 95.2 92.74 97.6
Friability (%) 0.162 0.198 0.190 0.112 0.105 0.107 0.043 0.067 0.0982
Hardness (Kg/cm2) 3.25 3.5 3.0 2.75 3.75 4 3.75 3.25 3.75
Similarity factor (f2) 28.69 38.03 29.12 30.67 32.05 40.99 72.22 43.46 70.64
using KBr mixing method on FTIR (FTIR-1700, Shimadzu,
Kyoto, Japan) for drug excipients interaction study (see
Figure 8).
3. Results andDiscussion
3.1. Result of Preliminary Screening. From the in vitro
dissolution study, it was found that hydrophobic binder
MCC wax and bees wax have more sustaining eﬀect on
the release of drug than stearic acid and cetyl alcohol it
is due to its hydrophobic nature. Hydrophilic binder PEG-
6000 gave good drug release compared to all the other
binders, which is due to its hydrophilic nature. HPMC K4M
(hydrophilic) was selected as a matrixing agent considering
its widespread applicability and excellent gelling activity in
controlled-release formulations. PVP was also selected in
formulation because it helps in releasing loading dose from
the formulation in the 1st hour which is required for the
therapeutic eﬀect of formulation.
3.2. Full Factorial Design. A statistical model incorporating
interactive and polynominal terms was used to evaluate the
responses
Y = b0 +b1X1 +b2X2 +b12X1X2 +b11X2
1 +b22X2
2,( 2 )
where Y is the dependent variable, b0 is the arithmetic mean
response of the 9 runs, and b1 is the estimated coeﬃcient
for the factor Xi. The main eﬀects (X1 and X2)r e p r e s e n t
the average result of changing 1 factor at a time from its
low to high values. The interaction terms (X1X2) show how
the response changes when two factors are simultaneously
changed. The polynomial terms (X2
1 and X2
2) are included to
investigate nonlinearity. The dissolution proﬁle for 9 batches
showed a variation (i.e., initial 1hr release ranging from
43.22% to 81.33% and drug release after 8hr ranging from
96.82% to 100%). The ﬁtted equations (full and reduced)
relating the responses, Q1, Q4,a n dQ8,d i ﬀusion coeﬃcient
(n), and release rate constant (K) to the transformed factor
are shown in the Table 3. The polynomial equations can be
used to draw conclusions after considering the magnitude of
coeﬃcient and the mathematical sign it carries (i.e., negative
or positive). Table 4 shows the results of analysis of variance
(ANOVA), which was performed to identify insigniﬁcant
factors. Data were analyzed using Design of Expert version
8.
R2 values for Q1, Q4,d i ﬀusion coeﬃcient (n), and
release rate constant (K) are 0.7774, 0.7122, 0.8135, and
0.7867, respectively, indicating good correlation between
dependent and independent variables. The low R2 value,
0.6055 for Q8, indicates poor correlation between dependent
and independent variables showing that drug release at 8hr
is less dependent on selected variables. The reduced models
were developed for response variables by omitting the insig-
niﬁcant terms with P>. 1000. The terms with P<. 10006 ISRN Pharmaceutics
Table 3: Summary of the results of regression analysis.
Q1
Response (Q1) b0 b1 b2 b12 b11 b22
FM 68.16 −3.85 −13.60 0.3525 −0.296 −6.91
RM 63.14 — −13.91 — — —
Q4
Response (Q6) b0 b1 b2 b12 b11 b22
FM 97.27 −2.11 −8.67 −0.367 −3.63 −6.30
RM 90.48 — −8.60 — — —
Q8
Response (Q8) b0 b1 b2 b12 b11 b22
FM 101.06 −0.055 −1.88 −0.0825 −1.59 −2.45
RM 98.715 −1.35
n
Response (n) b0 b1 b2 b12 b11 b22
FM 0.1704 0.0276 0.103 −0.00098 0.0093 0.049
RM 0.2135 — 0.109 — — —
K
Response (K) b0 b1 b2 b12 b11 b22
FM 0.7362 −0.039 −0.153 0.00095 −0.0098 −0.0823
RM 0.6723 −0.157
FM = full model, RM = reduced model.
were considered statistically signiﬁcance and retained in
the reduced model. The coeﬃcients for full and reduced
models for response variables are shown in Table 4.T h e
signiﬁcance levels of the coeﬃcients in the Q8 were found to
be insigniﬁcant at P>. 1000 and, hence, do not contribute
signiﬁcant information to the prediction of Q8.
3.3. Full and Reduced Model for Q1. The signiﬁcance levels
of the coeﬃcients b1, b11, b22,a n db12 were found to be
P = .4583, .9722,.4441, and.9534, respectively, so they were
omitted from the full model to generate a reduced model
[22]. The results of statistical analysis are shown in Table 4.
The coeﬃcients b0 and b2 were found to be signiﬁcant at
P<. 1000; hence, they were retained in the reduced model.
The reduced model was tested in proportion to determine
whether the coeﬃcients b1, b11, b12,a n db22 contribute
signiﬁcant information to the prediction of Q1. The results
of model testing are shown in Table 4. The critical value of F
for α = 0.1 is equal to 5.34 (df = 4,3). Since the calculated
value (F = 0.414) is less than the critical value (F = 5.34),
it may be concluded that the interaction terms b1, b11, b12,
and b22 do not contribute signiﬁcantly to the prediction of
Q1 and can be omitted from the full model to generate the
reduced model.
3.4. Full and Reduced Model for Q4. The signiﬁcance levels
of the coeﬃcients b1, b11, b22,a n db12 were found to be
P = .6023, .5762, .390, and .9344, respectively, so they
were omitted from the full model to generate a reduced
model. The results of statistical analysis are shown in Table 4.
The coeﬃcients b0,a n db2 were found to be signiﬁcant at
P<. 1000; hence, they were retained in the reduced model.
Table 4: Calculations for testing the model in portions.
DF SS MS F R2
Q1
Regression Fcalc. = 0.414
FM 5 1295.88 259.176 2.095 0.7774 Ftable = 5.34
RM 1 1162.04 1162.042 14.11 0.6684 DF(4,3)
Error
FM 3 370.996 123.665
RM 7 576.251 82.322
Q4
Regression Fcalc. = 0.417
FM 5 588.807 117.76 1.48 0.7122 Ftable = 5.34
RM 1 444.104 444.104 8.39 0.5453 DF (4,3)
Error
FM 3 237.936 79.31
RM 7 370.317 52.9
Q8
Regression Fcalc. = 0.197
FM 5 38.474 7.694813 0.9211 0.6055 Ftable = 5.34
RM 1 11.0432 11.0432 2.44 0.2587 DF (4,3)
Error 8.353
FM 3 25.05915 4.5191
RM 7 31.6339
n
Regression Fcalc.= 0.571
FM 5 0.07328 0.0146 2.61 0.8135 Ftable=5.34
RM 1 0.07128 0.07128 16.88 0.7069 DF(4,3)
Error
FM 3 0.01679 0.005597
RM 7 0.02955 0.004222
K
Regression Fcalc.=0.439
FM 5 0.1639 0.0327 2.21 0.7867 Ftable=5.34
RM 1 0.1478 0.1478 14.7 0.677 DF (4,3)
Error
FM 3 0.0444 0.0148
RM 7 0.0704 0.0101
DF, degree of freedom; SS, sum of squares; MS, mean of squares; R2,
regression coeﬃcient; FM, full model; RM, reduced model.
The reduced model was tested in proportion to determine
whether the coeﬃcients b1, b11, b12,a n db22 contribute
signiﬁcant information to the prediction of Q4. The results
of model testing are shown in Table 4. The critical value of F
for α = 0.1 is equal to 5.34 (df = 4,3). Since the calculated
value (F = 0.4172) is less than the critical value (F = 5.34),
it may be concluded that the interaction terms b1, b11, b12
and b22 do not contribute signiﬁcantly to the prediction of
Q4 and can be omitted from the full model to generate the
reduced model.
3.5. Full and Reduced Model for Diﬀusion Coeﬃcient (n).
The signiﬁcance levels of the coeﬃcients b1, b11, b22,a n d
b12 were found to be P = .4318, .8711, .4198, and 1.000,ISRN Pharmaceutics 7
Table 5: Kinetic treatment of dissolution data.
F1 F2 F3 F4 F5 F6 F7 F8 F9
Zero order
B 1.7188 3.850 1.9727 2.6722 2.8542 5.42 7.1859 5.7625 6.6357
A 89.50 71.37 87.95 83.46 81.25 62.96 42.74 59.76 43.639
R2 0.6497 0.8484 0.6567 0.7395 0.7897 0.8932 0.9799 0.9023 0.9775
First order
B 0.0081 0.0203 0.0095 0.0130 0.0140 0.0296 0.0449 0.0321 0.0338
A 1.95 1.8528 1.9418 1.9192 1.9083 1.8012 1.6650 1.7806 1.7414
R2 0.6438 0.8206 0.6482 0.7276 0.7699 0.8551 0.9483 0.8664 0.9394
Higuchi
B 7.6048 16.077 8.710 11.572 69.396 22.35 28.5 23.64 26.37
A 81.73 55.93 79.075 71.90 12.119 41.81 16.90 37.51 19.75
R2 0.7375 0.9088 0.7429 0.8216 0.8602 0.9439 0.9974 0.9497 0.9962
Hixon Crowell
B −0.028 −0.0678 −0.0327 −0.044 −0.0480 −0.0976 −0.141 −0.105 −0.131
A 0.1726 0.4946 0.1998 0.2764 0.3136 0.6578 1.0844 0.7219 1.069
R2 −0.645 −0.8300 −0.6507 −0.7316 −0.7765 −0.8684 −0.9605 −0.8792 −0.9594
Korsmeyer and Peppas
B 0.0837 0.187 0.097 0.128 0.133 0.267 0.379 0.288 0.356
A −0.0621 −0.163 −0.0711 −0.095 −0.105 −0.219 −0.355 −0.240 −0.350
R2 0.8201 0.9435 0.8229 0.8886 0.9109 0.962 0.998 0.968 0.997
B = slope, A = intercept, R2= square of correlation coeﬃcient, and n= diﬀusion exponent.
respectively, so they were omitted from the full model to
generate a reduced model. The results of statistical analysis
are shown in Table 4. The coeﬃcients b0 and b2 were
found to be signiﬁcant at P<. 1000; hence, they were
retained in the reduced model. The reduced model was
tested in proportion to determine whether the coeﬃcients
b1, b11, b12,a n db22 contribute signiﬁcant information to
the prediction of diﬀusion coeﬃcient (n). The results of
model testing are shown in Table 4. The critical value of F
for α = 0.1 is equal to 5.34 (df = 4,3). Since the calculated
value (F = 0.5717) is less than the critical value (F = 5.34),
it may be concluded that the interaction terms b1, b11, b12,
and b22 do not contribute signiﬁcantly to the prediction of
diﬀusion coeﬃcient (n) and can be omitted from the full
model to generate the reduced model.
3.6. Full and Reduced Model for Release Rate Constant (K).
The signiﬁcance levels of the coeﬃcients b1, b11, b22,a n d
b12 were found to be P = .4880, .9164, .4095, and .9882,
respectively, so they were omitted from the full model to
generate a reduced model. The results of statistical analysis
are shown in Table 4. The coeﬃcients b0 and b2 were
found to be signiﬁcant at P<. 1000; hence, they were
retained in the reduced model. The reduced model was
tested in proportion to determine whether the coeﬃcients
b1, b11, b12,a n db22 contribute signiﬁcant information to
the prediction of release rate constant (K). The results of
model testing are shown in Table 4. The critical value of F
for α = 0.1 is equal to 5.34 (df = 4,3). Since the calculated
value (F = 0.5717) is less than the critical value (F = 5.34), it
maybeconcludedthattheinteractiontermsb1, b11, b12,and
b22 donotcontributesigniﬁcantlytothepredictionofrelease
rate constant (K) and can be omitted from the full model
to generate the reduced model. To demonstrate graphically
the eﬀect of the ratio of polymer (HPMC K4M: PVP)
and concentration of melt binder (PEG 6000), the response
surfaceplotsweregeneratedbyusingDesignexpert8.0.2trial
version software for the dependent variables Q1,Q 4,Q 8 (%
drug release after 1, 4, 8 hours, resp.), diﬀusion coeﬃcient
(n), release rate constant (K) and shown in Figures 2, 3, 4, 5,
and 6 respectively.
3.7. Kinetic Modeling of Dissolution Data. The kinetics of
the dissolution data were well ﬁtted to zero order, Higuchi
model, and Krossmayer-Peppas model as evident from
regression coeﬃcients in Table 5. In case of the controlled-
release formulations, diﬀusion, swelling, and erosion are
the three most important rate controlling mechanisms.
Formulation containing swelling polymers show swelling as
well as diﬀusion mechanism because the kinetic of swelling
includes relaxation of polymer chains and imbibitions of
water, causing the polymer to swell and changing it from
a glassy to rubbery state. The value of diﬀusion exponent
n for most factorial formulations is between 0.084 and
0.379 (Table 5) indicating Fickian drug release from the
formulations [23, 24].
3.8. Comparison of Dissolution Proﬁles for Selection of Opti-
mum Batch. The values of similarity factor (f2) for the batch
F7 showed maximum 72.22 (Table 2); hence, it was selected
as optimum batch.8 ISRN Pharmaceutics
3.9. Fourier Transform Infrared Spectroscopy. The Zolpidem
tartrate exhibits peak due to amide and alkenes group. It was
observed that there were no changes in these main peaks
in the FTIR spectra of a mixture of drug and polymers
(Figure 3); hence, it was concluded that there were no
physical or chemical interactions of Zolpidem with PEG
6000, PVP, and HPMC K4M.
4. Conclusion
From the present investigation, it was concluded that the
concentrations of PEG 6000 as a melt binder have more
pronounced eﬀect than the ratio of HPMC K4M and PVP
K30 polymers on drug release from controlled-release tablet
formulation and are useful to produced tablet dosage form
with desirable drug release pattern.
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